PAYX
53
2
R
71
4
EOG
58
2
CTSH
56
2
BMY
60
2
KLAC
47
4
LNC
39
3
PEP
48
6
BAC
53
3
PPL
54
-5
HON
67
2
PYPL
54
2
FLR
58
3
UPS
60
9
SE
61
-4
LH
43
-2
CA
38
6
BBY
46
10
GOOG
50
-3
JWN
48
6
PAYX
53
2
R
71
4
EOG
58
2
CTSH
56
2
BMY
60
2
KLAC
47
4
LNC
39
3
PEP
48
6
BAC
53
3
PPL
54
-5
HON
67
2
PYPL
54
2
FLR
58
3
UPS
60
9
SE
61
-4
LH
43
-2
CA
38
6
BBY
46
10
GOOG
50
-3
JWN
48
6
Financhill
Back

Spero Therapeutics 10K Form

Sell
15

SPRO
Spero Therapeutics

Last Price:
1.18
Seasonality Move:
7.16%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SPRO News And Ratings

See the #1 stock for the next 7 days that we like better than SPRO

SPRO Financial Statistics

Sales & Book Value

Annual Sales: $96.74M
Cash Flow: $12.76M
Price / Cash Flow: 0
Annual Sales: $1.21
Price / Book: 0.97

Profitability

EPS (TTM): 0.08000
Net Income (TTM): $3.51M
Gross Margin: $7.4M
Return on Equity: 4.36%
Return on Assets: 2.37%

Spero Therapeutics Earnings Forecast

Key Spero Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for SPRO is 54.81%.
  • The Selling, General & Administrative Expenses for SPRO have been equal to 26.42% of Gross Profit Margin.
  • The Research & Development expenses have been 53.18% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of SPRO is 23.58% of Total Revenues.
  • Per Share Earnings over the last 19 years have been positive in 8 years.

Spero Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SPRO
CUSIP: 84833T
Website: sperotherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.68
Quick Ratio: 2.64

Price-to-Earnings

Trailing P/E Ratio: 2.7
Forward P/E Ratio: 0

SPRO Technical Analysis vs Fundamental Analysis

Sell
15
Spero Therapeutics (SPRO) is a Sell

Is Spero Therapeutics a Buy or a Sell?